These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18209721)

  • 1. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.
    Gerna G; Lilleri D; Caldera D; Furione M; Zenone Bragotti L; Alessandrino EP
    Bone Marrow Transplant; 2008 May; 41(10):873-9. PubMed ID: 18209721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
    J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
    Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
    Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
    Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Gerna G; Lilleri D; Zecca M; Alessandrino EP; Baldanti F; Revello MG; Locatelli F
    Haematologica; 2005 Apr; 90(4):526-33. PubMed ID: 15820949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
    Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.
    Gerna G; Lilleri D; Callegaro A; Goglio A; Cortese S; Stroppa P; Torre G
    Transplantation; 2008 Jul; 86(1):163-6. PubMed ID: 18622294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial.
    Gerna G; Baldanti F; Lilleri D; Parea M; Torsellini M; Castiglioni B; Vitulo P; Pellegrini C; Viganò M; Grossi P; Revello MG
    Transplantation; 2003 Apr; 75(7):1012-9. PubMed ID: 12698090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
    Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
    Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HHV-6-DNAemia related to CMV-DNAemia after liver transplantation.
    Härmä M; Loginov R; Piiparinen H; Halme L; Höckerstedt K; Lautenschlager I
    Transplant Proc; 2005 Mar; 37(2):1230-2. PubMed ID: 15848678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies.
    Muñoz-Cobo B; Solano C; Costa E; Bravo D; Clari MÁ; Benet I; Remigia MJ; Montoro J; Navarro D
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1602-11. PubMed ID: 21871245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia.
    Lilleri D; Gerna G; Furione M; Bernardo ME; Giorgiani G; Telli S; Baldanti F; Locatelli F
    Blood; 2007 Oct; 110(7):2757-60. PubMed ID: 17579182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring human cytomegalovirus infection in transplant recipients.
    Baldanti F; Lilleri D; Gerna G
    J Clin Virol; 2008 Mar; 41(3):237-41. PubMed ID: 18203657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
    Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK
    Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia.
    Pillet A; Mengelle C; Basse G; Ribes D; Kamar N; Muscari F; Lavayssière L; Suc B; Esposito L; Peron JM; Rostaing L
    Transplant Proc; 2006 Sep; 38(7):2335-8. PubMed ID: 16980083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients.
    Gerna G; Baldanti F; Lilleri D; Parea M; Alessandrino E; Pagani A; Locatelli F; Middeldorp J; Revello MG
    J Clin Microbiol; 2000 May; 38(5):1845-53. PubMed ID: 10790111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients.
    Cortez KJ; Fischer SH; Fahle GA; Calhoun LB; Childs RW; Barrett AJ; Bennett JE
    J Infect Dis; 2003 Oct; 188(7):967-72. PubMed ID: 14513415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring transplant patients for human cytomegalovirus: Diagnostic update.
    Gerna G; Lilleri D
    Herpes; 2006 May; 13(1):4-11. PubMed ID: 16732996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.